Role and utility of COVID-19 laboratory testing in low-income and middle-income countries: protocol for rapid evidence synthesis

Oijambo Kevin Ouma,1,2 Kisangala Ephraim,2,3 Nakalembe Loyce,2,4 Eve Namisango,2,5 Fred Nalugoda,2,6 Regina Ndagire,2,3 Rachel Nante Wangi,2,3 Brenda Allen Kawala,2,7 Thomas Katalo,2,8 Allen Eva Okullo,2,9 Robert Apunyo,2 Daniel Semakula,2,10 Ash Luwambo,2,11 Alison Annet Kinengyere,2,12 Nelson Sewankambo,2,13 Sheila N Balinda,2,14 Moses Ocan,2,15 Ekwaro A Obuku,2,16

ABSTRACT

Introduction Accurate and affordable laboratory testing is key to timely diagnosis and appropriate management of patients with COVID-19. New laboratory test protocols are released into the market under emergency use authorisation with limited evidence on diagnostic test accuracy. As such, robust evidence on the diagnostic accuracy and the costs of available tests is urgently needed to inform policy and practice especially in resource-limited settings. We aim to determine the diagnostic test accuracy, cost-effectiveness and utility of laboratory test strategies for COVID-19 in low-income and middle-income countries.

Methods and analysis This will be a multistaged, protocol-driven systematic review conducted in line with the Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) guidelines for diagnostic test accuracy studies. We will search for relevant literature in at least six public health databases, including PubMed, Google Scholar, MEDLINE, Scopus, Web of Science and the WHO Global Index Medicus. In addition, we will search Cochrane Library, COVID-END and grey literature databases to identify additional relevant articles before double-screening and abstraction of data. We will conduct a structured narrative and quantitative synthesis of the results guided by the Fryback and Thornbury framework for assessing a diagnostic test. The primary outcome is COVID-19 diagnostic test accuracy. Using the GRADE approach specific to diagnostic accuracy tests, we will appraise the overall quality of evidence and report the results following the original PRISMA statement. The protocol is registered with the International Prospective Register of Systematic Reviews (PROSPERO; [https://www.crd.york.ac.uk/prospero/]).

Ethics and dissemination Ethical review was done by the School of Biomedical Sciences Research Ethics Committee and the Uganda National Council for Science and Technology. The published article will be accessible to policy and decision makers. The findings of this review will guide clinical practice and policy decisions and highlight areas for future research.

Strengths and limitations of this study

- The study will contribute to strengthening the evidence base on the effectiveness of laboratory testing strategies for COVID-19 in hospitals and community populations in low-income and middle-income countries (LMICs).
- The protocol has been written following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines.
- The GRADE system will be used to ascertain the strength of the evidence base for each outcome and to report data for the primary outcome in a ‘Summary of Findings table’.
- The review is limited to evidence from LMICs.
- Non-English databases will not be searched and this may introduce language bias.

PROSPERO registration number CRD42020209528.

BACKGROUND

COVID-19 is a viral pneumonia caused by a novel coronavirus, initially named 2019 novel coronavirus (2019-nCoV) and subsequently changed to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) by the International Committee on Taxonomy of Viruses.1 Initial cases of COVID-19 were identified in Wuhan, Hubei Province, China in December 2019. The epidemic later spread to other countries, reaching Egypt and Africa on 14 February 2020. On 11 March 2020, the disease was declared by the WHO a global pandemic.2

Proper clinical management and control of this pandemic warrant laboratory diagnosis and testing of appropriate specimens from patients meeting the suspected case
definition for COVID-19 as a priority. Detection of viral nucleic acid using nucleic acid amplification tests such as reverse transcription-PCR (RT-PCR) is the gold standard for diagnosis of SARS-CoV-2 infection. Real-time RT-PCR assays are characterised by rapid detection and high sensitivity and specificity and hence recommended for diagnosis of early COVID-19 infections.

The RT-PCR assay is complex, time-consuming and associated with risk of eliciting false-negative and false-positive results because it is easily affected by factors such as collection time, sample type and nature of sample preservation. Each PCR test may cost hundreds of dollars and requires the use of sophisticated equipment and expensive reagents. According to the Ministry of Health in Uganda, each PCR diagnostic test (WHO-approved) costs approximately $65. This high cost is a potential barrier to majority of the population. Furthermore, this method is unable to meet the principles of early detection, early isolation and early treatment and hence not favourable for prevention and control of the epidemic.

Existing evidence also highlights inconsistencies in the diagnostic accuracy of these assays. More so, most of the evidence on diagnostic accuracy is largely from developed countries, where the COVID-19 curves are flattening. Low-income and middle-income settings are now the epicentre of the pandemic, yet evidence on the diagnostic accuracy of existing tests is largely lacking. This review addresses this knowledge gap on the diagnostic accuracy of available assays to further strengthen the role of testing in the COVID-19 response in these settings.

Rationale
According to a systematic review and meta-analysis of articles on diagnostic accuracy from China, Denmark, Italy, Japan, Spain, Sweden, UK, USA and Germany, the pooled sensitivity of ELISA measuring IgG or IgM was 84.3%, for lateral flow immunoassays was 66.0%, and for chemiluminescent immunoassays was 97.8%. In the same study, the pooled specificity ranged from 96.6% to 99.7%. In a similar meta-analysis of studies from North and South America, Europe and China, the average sensitivity of rapid antigen tests was 56.2% and the average specificity was 99.5%. In the same study, the average sensitivity of rapid immunoassays was 95.2% and the specificity was 98.9%. Based on the findings of these review studies, the diagnostic accuracy of these assays varies and remains questionable. Also, these reviews may not be used to depict the diagnostic accuracy of assays in low-income and middle-income countries (LMICs). Therefore, there is a need to review the diagnostic test accuracy of these tests in LMICs as they are key in the fight against the pandemic.

According to Fryback and Thornbury, it is necessary to assure the efficacy of a diagnostic technique at six levels. This involves determining the technical quality (does the test measure what it purports to measure?), diagnostic accuracy (sensitivity and specificity of the test), diagnostic thinking efficacy (does the test help clinicians come to a diagnosis?), therapeutic efficacy (does it aid in planning treatment?), whether patients benefit from the use of the test, and the societal efficacy (cost–benefit and cost-effectiveness). This review therefore seeks to generate evidence-based recommendations that support the effectiveness of testing strategies and the utility of testing in the control and management of COVID-19 in LMICs through a rapid review.

METHODS
The evidence synthesis will be protocol-driven. The protocol is registered with the International Prospective Register of Systematic Reviews (PROSPERO; https://www.crd.york.ac.uk/prospero/) and will be published in a peer-reviewed journal after further development following the statement of the Preferred Reporting Items for Systematic Reviews and Meta-Analyses guidelines for diagnostic test accuracy studies (PRISMA-DTA).

Review question
The review question is: what is the effectiveness of laboratory testing strategy for COVID-19 in hospitals and community populations in LMICs?

Table 1: The PICOST model for the review question

<table>
<thead>
<tr>
<th>PICOST element</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td>Population/setting</td>
<td>Adults (18 years and above) in LMIC settings as defined by the World Bank.</td>
</tr>
<tr>
<td>Intervention/exposure</td>
<td>New index laboratory test; peripheral laboratory testing strategy or mass testing (pooling).</td>
</tr>
<tr>
<td>Comparator</td>
<td>Reference tests for COVID-19 (gold standard) and the current standard of testing strategy (centralised and individualised).</td>
</tr>
<tr>
<td>Outcome</td>
<td>Types of tests available; diagnostic test accuracy (sensitivity, specificity, predictive values); costs and cost-effectiveness of the tests; relative risk of testing strategy.</td>
</tr>
<tr>
<td>Study design</td>
<td>Diagnostic accuracy studies of observational design (cross-sectional, case–control and cohort studies), and diagnostic strategy studies of experimental design or randomised trials on COVID-19 laboratory testing.</td>
</tr>
<tr>
<td>Timing of outcome assessment</td>
<td>72 hours.</td>
</tr>
</tbody>
</table>

LMIC, low-income and middle-income country.
Outcomes
The primary outcome is the diagnostic test accuracy (sensitivity and specificity) of COVID-19 laboratory test methods in LMICs. The secondary outcomes are the types of COVID-19 tests that are available in LMICs, the effect (relative risk) of the testing strategy, and the cost and cost-effectiveness (incremental cost-effectiveness ratio, ICER) of the various COVID-19 testing algorithms.

Eligibility and selection of studies
Studies will be included if they are published in peer-reviewed journals from January 2020 to present; are studies about PCR assay tests for COVID-19 and rapid point-of-care diagnostic tests; studies conducted on adults (18 years and above) in LMIC settings; observational studies (cross-sectional, case-control and cohort studies), systematic reviews and randomised controlled trials on COVID-19 laboratory testing.

We intend to exclude studies about index COVID-19 tests without a reference standard; clinical COVID-19 diagnosis alone without verification with any laboratory test; modelling studies on COVID-19 testing; manufacturers' brochures on COVID-19 testing; studies on children <18 years as they are an unlikely source of transmission; or COVID-19 laboratory tests not recommended by the WHO.

Data sources
Article search will be performed on the following databases: PubMed, Google Scholar, MEDLINE, Scopus, Web of Science and the WHO Global Index Medicus. Manual searches will be conducted in websites of organisations championing COVID-19 management for grey literature, including but not limited to manufacturers of COVID-19 laboratory tests; Centers for Disease Control and Prevention in Africa, China, Europe and the USA; the WHO; specialised research institutions in Africa, such as the Uganda Virus Research Institute and Kenya Medical Research Institute; and departments of health such as the Ministry of Health in Uganda, South Africa (Southern Africa), Nigeria (West Africa), and Rwanda and Kenya (Eastern Africa). A list of key experts in diagnosis and testing will be developed and contacted to obtain more information on this subject matter.

Search strategy
The search strategy was developed by our information science specialist (AAK). This search strategy was piloted in PubMed to test for precision of appropriate articles retrieved. We will identify additional relevant articles by manually searching the reference list of selected articles, consulting experts in this field, and searching targeted libraries and websites such as Cochrane and COVID-END.

Search terms
We will use the following search terms: COVID-19, 2019-nCoV, novel corona virus disease, Wuhan pneumonia, severe acute respiratory syndrome related corona virus-2, SARS-CoV-2 and corona virus disease-19. We will also use the following Medical Subject Heading (MeSH) terms to identify the tests: testing, tests, diagnosis, diagnostics, COVID-19 ‘point of care tests’, Wuhan corona virus tests, laboratory test, corona virus tests and corona virus testing. The search will be limited to LMICs and the search terms will be combined using Boolean operators (AND, OR, NOT) in the electronic search engines. This search string from PubMed will be adapted to the syntax of other targeted databases for this review (online supplemental file 1).

Data management, screening and selection
The EndNote software will be used for the initial management of references of the search results. These will later be exported to online open access review management software for screening, coding and analysis. The retrieved articles will be exported to EndNote and duplicates will be removed. The studies will then be screened in duplicate following a priori criteria for eligibility (online supplemental file 2). The screening will be performed independently by two review team pairs (OKO, KE, NL and EN), and any disagreements between the reviewers will be resolved through discussion, and later independent senior reviewers (EAO and MO) will validate the results for quality control and assurance to ensure completeness and correctness.

The following data will be extracted from the articles in a table format: author, year of publication, author affiliation, study design, funding source and other PICOST items, as shown in table 1. The outcome data items are the types of tests available, diagnostic test accuracy (sensitivity, specificity, predictive values), costs and cost-effectiveness of the tests, and relative risk of the testing strategy (online supplemental file 3).

Framework for review synthesis
Our review will be guided by the Fryback and Thornbury [10] framework to establish diagnostic test efficacy, focusing on three levels. These are ‘technical efficacy’, ‘diagnostic accuracy efficacy’ and ‘societal efficacy’. This six-tiered model is a continuum for diagnostic test efficacy and assesses the effectiveness of laboratory testing strategy for COVID-19 among hospitals and community populations in LMICs. The other levels are ‘diagnostic thinking efficacy’, ‘therapeutic efficacy’ and ‘patient outcome efficacy’ and are less applicable to this review.

Briefly, the following are the three levels of interest: (1) Technical efficacy concerns physical parameters describing the technical quality of a diagnostic test. These are derived under optimal laboratory conditions.
and are prerequisites to consideration of efficacy at all subsequent levels. These include the turnaround time, type of the sample and diagnostic test algorithm, that is, single test or series of tests. (2) Diagnostic accuracy efficacy is characterised by the yield of abnormal or normal diagnoses in a case series. This will be measured as a percentage of the correct diagnoses in the case series, the positive and negative predictive values, and the sensitivity and specificity of a given COVID-19 laboratory diagnostic test. (3) Societal efficacy goes beyond the individual risk and benefit of a given COVID-19 test and denotes the cost borne by the society as whole for the diagnostic test to be acceptable for use regardless of the efficacy of the test on individual patient application at any other level. We will estimate whether a given COVID-19 laboratory test is efficacious to an extent that it is an efficient use of resources and provides medical benefits to the society given the low-income and middle-income setting. We will calculate the cost per unit output (measures from level 1 to 6) of a given COVID-19 diagnostic test and the cost-effectiveness by calculating the ICER as a difference between the costs of two given COVID-19 laboratory tests divided by the difference in their effects (measures from level 2).

To determine the relative risk/effect of the testing strategy, we will conduct regression analysis with a random effects model and estimate the relative risk ratios to identify the types of strategies which are associated with optimal strategies associated with optimal specificity and sensitivity cut-offs. Relative risk ratios and CIs will be reported.

Data synthesis
The syntheses will be in the form of summary of findings tables, simple graphs and forest plots, as applicable, using STATA V.15. The Fryback and Thornbury framework will guide this synthesis. First, a structured narrative synthesis of the results will be conducted. This will describe the types of data available, including the tests and the study design. Second, the quantitative synthesis will be outcome-based considering the primary outcome (diagnostic test accuracy of COVID-19 laboratory tests) and the secondary outcomes (costs, cost-effectiveness, turnaround times and the diagnostic testing strategy: centralised versus peripheral; and targeted individual testing versus pooling of samples for scale-up). We will use mixed effects model with the Duckworth-Lewis-Stern method to calculate the overall target score for accuracy. Reporting of these findings will be in line with the PRISMA-DEA statement.

Risk of bias assessment
Two reviewers (EN, OKO, NL or KE) will independently evaluate the methodological quality using the Quality Assessment of Diagnostic Accuracy Studies approach (QUADAS-2 tool). Bias will be assessed by making judgements (high, low and unclear) on individual elements from five domains (selection bias, attrition bias, performance bias, reporting bias, detection bias and other biases, ie, conflict of interest). Any disagreements will be resolved through discussion and involvement of a senior reviewer (MO or EAO).

Publication bias
All included articles will be assessed for publication bias based on the asymmetry of the funnel plot and/ or Egger’s test, as appropriate; these are simple rank-based data augmentation techniques which have been proven to be accurate in assessing publication bias due to missing studies. We will plot funnel plots and use the symmetry of the plots to detect the likelihood of publication bias among the articles included in the review. Graphically, in the absence of missing studies, the shape of the scatter plot resembles a symmetrical inverted funnel with a wide base and a narrow top. The presence of large ‘holes’—most often seen close to the bottom—or asymmetry in the plot indicates publication bias, but could also be explained by other factors such as study heterogeneity.

Heterogeneity
To assess the level of statistical heterogeneity in the articles, I² statistics will be used. The I² statistics will indicate percentage (%) heterogeneity that can be attributed to between-study variance. An I² of 25% indicates low heterogeneity, I² of 50% moderate heterogeneity and I² of 75% high heterogeneity. Subgroup analysis will be done on articles with low and moderate heterogeneity.

Quality assessment
To assess the quality of evidence from the reviews, we will use AMSTAR 2 (A Measurement Tool to Assess Systematic Reviews), which is a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions or both. The tool contains 10 domains against which the articles are assessed for quality. The overall quality of evidence will be assessed using a modified Grading of Recommendations Assessment, Development and Evaluation (GRADE) approach, where we will assign certainty of evidence ratings for the outcome variables listed above based on an approach developed by the GRADE Working Group and will be done in duplicate, with any disagreements resolved by consensus.

Ethics approval and consent to participate
The review protocol was reviewed and approved by the Makerere University School of Biomedical Sciences Institutional Review Board and the Uganda National Council for Science and Technology.

Patient and public involvement
There was no patient and public engagement in the design, interpretation or dissemination of the findings nor will it be required in this review since it will use already published data.
Author affiliations
1Department of Medicine, Clinical Epidemiology Unit, Makerere University College of Health Sciences, Kampala, Uganda
2Africa Centre for Systematic Reviews and Knowledge Translation, Makerere University College of Health Sciences, Kampala, Uganda
3Department of General Medicine, Karios Hospital, Kampala, Uganda
4Department of Pharmacology, College of Medicine and Health Sciences, King Ceasar University, Kampala, Uganda
5Cicely Saunders Institute of Palliative Care, Policy & Rehabilitation, King's College Hospital, London, UK
6School of Public Health, Rakai Health Sciences Program, Makerere University
7Department of Public Health, Institute of Medicine, Sahlgrenska Academy at University of Gothenburg, Gothenburg, Sweden
8Laboratory, Infectious Diseases Research Collaboration, Kampala, Uganda
9Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda
10Department of Medicine, Regional East African Community Health (REACH) Policy Initiative, Makerere University College of Health Sciences, Kampala, Uganda
11Directorate for ICT Support, Makerere University College of Health Sciences, Kampala, Uganda
12Albert Cook Library, Makerere University College of Health Sciences, Kampala, Uganda
13Department of Medicine, Makerere University College of Health Sciences, Kampala, Uganda
14Pathogen Genomics, Phenotype and Immunity, Uganda Virus Research Institute, Entebbe, Uganda
15Department of Pharmacology and Therapeutics, Makerere University College of Health Sciences, Kampala, Uganda
16Facultyt of Epidemiology and Population Health, London School of Hygiene and Tropical Medicine, London, UK

Twitter Brenda Allen Kawala @KawalaBrenda, Daniel Semakula @Dansemakula and Moses Ocan @MosesOcan

Acknowledgements We would like to acknowledge and thank MO and EAO for their guidance and unwavering support throughout the entire process of writing this protocol. This work would not be possible without accessing funding from the Africa Centre for Systematic Reviews and Knowledge Translation, College of Health Sciences, Makerere University, and the Clinical Epidemiology Unit, Makerere University, Kampala, Uganda.

Contributors Conception of the work: MO, EAO and NS. Acquisition of data: OKO, KE, NL, EN, FN, RN, RNW, BAK, TK, AEO, RA, DS, AL, AAK, NS, SNB, MO and EAO. Drafting the work: EN, NL, OKO and KE. Final approval: all authors. OKO, KE, NL, NE, MO, EAO and NS. Acquisition of data: OKO, KE, NL, EN, FN, RN, RNW, BAK, TK, AEO, RA, DS, AL, AAK, NS, SNB, MO and EAO reviewed and approved the final manuscript.

Funding This study is funded by the Makerere University Research and Innovation Fund (MakRIF-COVID-19 fund). The funder had no role in developing the protocol.

Competing interests None declared.

Patient consent for publication Not required.

Provenance and peer review Not commissioned; externally peer reviewed.

Supplemental material This content has been supplied by the author(s). It has not been vetted by BMJ Publishing Group Limited (BMJ) and may not have been approved the final manuscript. It includes any translated material, BMJ does not warrant the accuracy and reliability of the translations (including but not limited to local regulations, clinical guidelines, terminology, drug names and drug dosages), and is not responsible for any error and/or omissions arising from translation and adaptation or otherwise.

Open access This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.

ORCID iDs
Rachel Nante Wangi http://orcid.org/0000-0002-6589-2535
Thomas Katairo http://orcid.org/0000-0002-8991-1136
Daniel Semakula http://orcid.org/0000-0002-0806-213X
Moses Ocan http://orcid.org/0000-0002-8852-820X

REFERENCES